Novartis, Amgen and Banner Alzheimer’s Institute, in association with Alzheimer’s Disease International, today announced results from an online survey investigating perceptions of Alzheimer’s disease.

New research from UCL out tomorrow has highlighted the difference in diagnosis rates between black ethnic groups compared to white groups in the UK.

New research, which brings together the views of the world’s leading experts, has concluded that non-drug approaches should be prioritised in treating agitation in people with Alzheimer’s Disease.

New research has found that ten minutes of social interaction a day helps improve wellbeing for people with dementia in care homes.

New research has found that the cholesterol control drug, Gemfibrozil, reduces levels of amyloid and brain inflammation in mice.

New research shows that a genetic variant of the PLCG2 gene may reduce the risk of developing some dementias and healthy ageing.

New research shows a link between reducing amyloid in the brain and slowing cognitive decline.

New research shows that a study of the immunotherapy treatment Crenezumab has found it can reduce levels of the protein amyloid, associated with dementia.

A phase 1 trial, reported in Nature Communications, has found that blood‒brain barrier (BBB) can be non-invasively and reversibly opened in five patients with Alzheimer’s disease.

New research shows that a potential new drug to treat Alzheimer’s disease, Lanabecestat, has failed a phase 2/3 trial.

New research shows that air pollution could have an effect on cognitive ageing.

Research from the Systolic Blood Pressure Intervention Trial (SPRINT) shows that treatment to lower blood pressure can reduce Mild Cognitive Impairment (MCI).